Drug intelligence / Profile preview

[99mTc]Tc-N4-[alpha-Me-Trp8]MJ9

Development stage
Preclinical
Lead developer
University of Patras
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

[99mTc]Tc-N4-[alpha-Me-Trp8]MJ9 is a radiopharmaceutical imaging agent designed for single-photon emission computed tomography (SPECT). It is a derivative of the MJ9 peptide, a bombesin-like peptide antagonist that targets the gastrin-releasing peptide receptor (GRPR). The compound features an alpha-methyl tryptophan substitution at the Trp8 position, which was originally intended to improve metabolic stability for targeted radiotherapy. It is labeled with technetium-99m via a 6-carboxy-1,4,8,11-tetraazaundecane (N4) chelator. Preclinical studies in PC-3 tumor-bearing mice have demonstrated high GRPR affinity and improved pharmacokinetics compared to reference tracers, suggesting potential applications in imaging prostate cancer, breast cancer, and gastrointestinal stromal tumors.

Other names
99mTc-labeled N4-[alpha-Me-Trp8]MJ9technetium-99m N4-[alpha-methyl-tryptophan8]MJ9
02

Targets

GRPR (Gastrin-releasing peptide receptor)

Beyond the preview

Go deeper on [99mTc]Tc-N4-[alpha-Me-Trp8]MJ9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [99mTc]Tc-N4-[alpha-Me-Trp8]MJ9.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call